neoplasm
• pancreatic tumors and liver metastasis express high levels of glucagon and mice exhibit increased circulating glucagon levels indicating that tumors are glucagonoma
|
• mice develop pancreatic neuroendocrine tumors that are classified as metastatic islet cell carcinoma; tumors are nodular and highly vascularized
• marker analysis indicates that both the primary pancreatic tumor and the liver metastases are pancreatic neuroendocrine in origin
|
• metastasis to the liver and lymph node is seen; liver metastases are nodular and highly vascularized
• liver also contains many separate metastatic foci
|
• mice develop subcutaneous tumors infrequently at around 3-4 months of age; these tumors have a solid growth pattern and are consistent with high-grade vascular sarcoma
|
endocrine/exocrine glands
• pancreatic tumors and liver metastasis express high levels of glucagon and mice exhibit increased circulating glucagon levels indicating that tumors are glucagonoma
|
• mice develop pancreatic neuroendocrine tumors that are classified as metastatic islet cell carcinoma; tumors are nodular and highly vascularized
• marker analysis indicates that both the primary pancreatic tumor and the liver metastases are pancreatic neuroendocrine in origin
|
mortality/aging
• primary mortality is from metastatic pancreatic neuroendocrine disease with lethal onset beginning at around 22 weeks of age
• in rare instances, mice develop subcutaneous tumors and need to be euthanized at around 12-16 weeks of age and in even more rare cases, mice die as early as 8 weeks of age of unknown causes; these cases constitute about 12% of mice
|
homeostasis/metabolism
• mice show increased circulating glucagon levels at 4, 5 and 6 months but not at 2 months of age
|
growth/size/body
• 32% reduction in body weight of sick mutants
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
adenoma | DOID:657 | J:216559 | ||
pancreatic carcinoma | DOID:4905 |
OMIM:260350 |
J:216559 |